Also trades as: 0KCC.L (LSE) · $vol 0M
IMDX NASDAQ
Insight Molecular Diagnostics Inc.
1W: +4.3%
1M: -0.6%
3M: -27.7%
YTD: -55.9%
1Y: -52.3%
3Y: +14.5%
5Y: -95.1%
$3.16
+0.16 (+5.33%)
Weekly Expected Move ±14.9%
$2
$2
$3
$3
$4
Credit Risk of going bust: higher than 68% of companies Debt: 2.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.5%), Insight Molecular Diagnostics Inc. would be worth roughly what it owes.
Total debt $2.6M against a stock market value of $103.4M.
Distance to default 3.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.3M (short-term plus half of long-term), stock volatility 108.7%; Altman Z'' -55.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.5%), Insight Molecular Diagnostics Inc. would be worth roughly what it owes.
Total debt $2.6M against a stock market value of $103.4M.
Distance to default 3.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.3M (short-term plus half of long-term), stock volatility 108.7%; Altman Z'' -55.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
17 relationships17
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-06-14
Earliest Filing
2026-02-26
Latest Filing
partner: 13
target: 2
customer: 1
acquirer: 1
Counterparties (Filed by IMDX)
17 relationshipsCompanies named in IMDX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | DGX | partner | Agreement for specimen collection services related to GraftAssureCore test | 2026-02-26 | View |
| Oncocyte Corporation | — | partner | Original tenant entering lease amendment and waiver | 2025-01-08 | View |
| Induce Biologics USA, Inc. | — | partner | New tenant replacing Oncocyte in replacement lease | 2025-01-08 | View |
| Cushing Ventures, LLC | — | partner | Landlord entering lease amendment and replacement lease | 2025-01-08 | View |
| Oncocyte Corporation | OCX | partner | Partnered with Bio-Rad for global commercialization of GraftAssure assay | 2024-04-11 | View |
| Bio-Rad Laboratories | BIO-B | partner | Partnered with Oncocyte for global distribution and commercialization of GraftAssure assay | 2024-04-11 | View |
| Induce Biologics USA, Inc. | — | customer | Subtenant entering a sublease agreement for office space | 2023-09-20 | View |
| Cushing Ventures, LLC | — | partner | Landlord consenting to the sublease agreement | 2023-09-20 | View |
| Oncocyte Corporation | ONCY | target | Seller of the purchased shares in the Stock Purchase Agreement. | 2023-02-23 | View |
| Dragon Scientific, LLC | — | acquirer | Buyer of the purchased shares in the Stock Purchase Agreement. | 2023-02-23 | View |
| Razor Genomics, Inc. | — | target | Target company whose shares are being purchased in the Stock Purchase Agreement. | 2023-02-23 | View |
| Life Technologies Corporation | LIFE | partner | Terminated collaboration agreement with Oncocyte Corporation | 2023-02-13 | View |
| Oncocyte Corporation | ONCY | partner | Terminated collaboration agreement with Life Technologies Corporation | 2023-02-13 | View |
| Thermo Fisher Scientific Inc. | TMO | partner | Parent company of Life Technologies Corporation listed as notice recipient | 2023-02-13 | View |
| Oncocyte Corporation | OCX | partner | Announced a development and co-marketing agreement for IVD assays on Thermo Fisher Scientific's Genexus System. | 2022-01-18 | View |
| Thermo Fisher Scientific | TMO | partner | Entered into a collaboration with Oncocyte to expand access to precision oncology through co-development and co-marketin | 2022-01-18 | View |
| BTIG, LLC | — | partner | Sales agent for the Company's at-the-market stock offering | 2021-06-14 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-21 | Material Agreement; Exhibits | Agreement | View |
| 2026-08-10 | Earnings Release; Regulation FD; Other Events; Exhibits | View | |
| 2026-06-17 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-05-13 | Other Events | View | |
| 2026-04-30 | Other Events; Exhibits | View | |
| 2026-03-26 | Earnings Release; Exhibits | View | |
| 2026-02-26 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-02-12 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-02-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-02 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-09-19 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-02 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-06-17 | Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-05-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-17 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-03-24 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-10 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR